Jing, Chao
Wang, Junyun
Zhu, Mingyue
Bai, Zhigang
Zhao, Baoyi
Zhang, Jun
Yin, Jie
Yang, Xiaobao
Liu, Zongzhi
Zhang, Zhongtao
Deng, Wei http://orcid.org/0000-0001-5313-5599
Clinical trials referenced in this document:
Documents that mention this clinical trial
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
https://doi.org/10.1007/s00262-022-03174-9
Funding for this research was provided by:
National Natural Science Foundation of China Youth Science Foundation Project
National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Article History
Received: 27 August 2021
Accepted: 14 February 2022
First Online: 18 March 2022
Declarations
:
: The authors declare no potential conflicts of interest.
: The trial was approved by the ethics board of the Beijing Friendship Hospital affiliated to Capital Medical University and was done in accordance with the Declaration of Helsinki. All patients provided written informed consent.
Free to read: This content has been made available to all.